Teva Pharmaceutical Industries Ltd (NYSE:TEVA) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 37,244,528 shares, a decline of 11.3% from the July 13th total of 42,005,618 shares. Based on an average daily trading volume, of 6,526,679 shares, the days-to-cover ratio is presently 5.7 days.

Several equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a research note on Monday, July 9th. Citigroup boosted their target price on shares of Teva Pharmaceutical Industries from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Wednesday, June 27th. Goldman Sachs Group boosted their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Monday, June 25th. Royal Bank of Canada restated a “hold” rating and set a $19.00 target price on shares of Teva Pharmaceutical Industries in a research report on Tuesday, July 31st. Finally, Wells Fargo & Co upgraded shares of Teva Pharmaceutical Industries from an “underperform” rating to a “market perform” rating in a research report on Monday, June 18th. Nine analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eight have given a buy rating to the company’s stock. Teva Pharmaceutical Industries has a consensus rating of “Hold” and an average target price of $20.45.

In other news, EVP Sven Dethlefs acquired 2,000 shares of the company’s stock in a transaction on Friday, August 3rd. The shares were bought at an average cost of $21.92 per share, with a total value of $43,840.00. Following the purchase, the executive vice president now owns 6,445 shares of the company’s stock, valued at approximately $141,274.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Iris Beck Codner sold 4,165 shares of the business’s stock in a transaction on Thursday, August 9th. The shares were sold at an average price of $22.70, for a total transaction of $94,545.50. Following the completion of the transaction, the executive vice president now directly owns 8,290 shares in the company, valued at $188,183. The disclosure for this sale can be found here. Insiders own 0.43% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the stock. Pinnacle Associates Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 11.0% in the 2nd quarter. Pinnacle Associates Ltd. now owns 22,862 shares of the company’s stock worth $556,000 after buying an additional 2,272 shares in the last quarter. ARK Investment Management LLC raised its stake in Teva Pharmaceutical Industries by 9.2% in the 2nd quarter. ARK Investment Management LLC now owns 30,487 shares of the company’s stock valued at $741,000 after purchasing an additional 2,561 shares during the last quarter. Wetherby Asset Management Inc. raised its stake in Teva Pharmaceutical Industries by 27.5% in the 1st quarter. Wetherby Asset Management Inc. now owns 13,265 shares of the company’s stock valued at $227,000 after purchasing an additional 2,857 shares during the last quarter. HPM Partners LLC raised its stake in Teva Pharmaceutical Industries by 25.4% in the 2nd quarter. HPM Partners LLC now owns 14,657 shares of the company’s stock valued at $356,000 after purchasing an additional 2,971 shares during the last quarter. Finally, Point View Wealth Management Inc. raised its stake in Teva Pharmaceutical Industries by 4.4% in the 2nd quarter. Point View Wealth Management Inc. now owns 71,603 shares of the company’s stock valued at $1,741,000 after purchasing an additional 2,996 shares during the last quarter. Institutional investors and hedge funds own 64.95% of the company’s stock.

Teva Pharmaceutical Industries stock opened at $24.22 on Friday. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $25.14. The company has a debt-to-equity ratio of 1.86, a quick ratio of 0.69 and a current ratio of 1.03. The stock has a market capitalization of $22.86 billion, a P/E ratio of 6.16, a price-to-earnings-growth ratio of 2.80 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, August 2nd. The company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.64 by $0.14. Teva Pharmaceutical Industries had a negative net margin of 47.98% and a positive return on equity of 19.92%. The business had revenue of $4.70 billion for the quarter, compared to analyst estimates of $4.75 billion. During the same period in the previous year, the firm earned $1.02 EPS. The business’s revenue for the quarter was down 17.8% compared to the same quarter last year. analysts forecast that Teva Pharmaceutical Industries will post 2.67 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: Diversification

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.